Annual Clinical and Economic Burden of Medically Attended Lower Respiratory Tract Illnesses Due to Respiratory Syncytial Virus among US Infants Aged <12 Months.

Autor:	Houde L; Avalere Health, Boston, MA, USA., Law AW; Pfizer Inc., New York, NY, USA., Averin A; Avalere Health, Boston, MA, USA., Weycker D; Avalere Health, Boston, MA, USA., Cane A; Pfizer Inc., New York, NY, USA., Pugh S; Pfizer Inc., New York, NY, USA., Shea KM; Pfizer Inc., New York, NY, USA.
Jazyk:	angličtina
Zdroj:	The Journal of infectious diseases [J Infect Dis] 2024 Nov 15. Date of Electronic Publication: 2024 Nov 15.
DOI:	10.1093/infdis/jiae544
Abstrakt:	We developed a model to project the expected annual clinical and economic burden of medically attended lower respiratory tract illnesses due to respiratory syncytial virus (RSV-LRTI) among US infants aged <12 months by combining information on population size, disease rates, mortality rates, and unit costs. Among the 3.7 million US infants aged <12 months each year, a total of 592,700 cases of RSV-LRTI (hospitalizations: 48,499; emergency department visits: 144,599; outpatient clinic visits: 399,602) were projected to occur, yielding total annual costs of $1.6 billion. The annual burden of RSV-LRTI among US infants is considerable, especially among those aged <3 months, who account for 43% of total costs. (© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu